Gelteq Limited (GELS) Income Statement

NASDAQ: GELSRevenue, profits, margins and EPS over 6 years.

GELS FY2025 at a glance

Fiscal year ended June 30, 2025 · Australian dollars
Revenue
A$165,645
FY2025 · hover or tap a bar for each year
FY2020: A$0FY2021: A$0FY2022: A$147,536FY2023: A$79,843 (−45.9%)FY2024: A$0 (−100.0%)FY2025: A$165,645
FY2020FY2025
Gross profit
A$165,645
FY2025 · hover or tap a bar for each year
FY2021: A$0FY2022: A$52,662FY2023: A$30,918 (−41.3%)FY2024: A$0 (−100.0%)FY2025: A$165,645
FY2020FY2025
Operating income
−A$5.5M
FY2025 · hover or tap a bar for each year
FY2021: −A$647,624FY2022: −A$3.2MFY2023: −A$3.1MFY2024: −A$2.9MFY2025: −A$5.5M
FY2020FY2025
Net income
−A$6.6M
FY2025 · hover or tap a bar for each year
FY2020: −A$375,587FY2021: −A$648,921FY2022: −A$3.4MFY2023: −A$3.5MFY2024: −A$3.5MFY2025: −A$6.6M
FY2020FY2025
Net profit margin
−4,011.9%
FY2025 · hover or tap a point for each year
FY2022: −2,283.4%FY2023: −4,391.4% (−2,108.0 pts)FY2025: −4,011.9%
FY2020FY2025

GELS revenue and net income

RevenueNet incomeNet margin (right axis)

Where GELS's revenue goes

FY2025
Revenue
A$165,645100.0%
Cost of revenue
A$00.0%
Gross profit
A$165,645100.0%
Research & development
−A$628,606−379.5%
Sales, general & admin
−A$2.2M−1,342.1%
Other operating expenses
−A$2.8M−1,696.1%
Operating income
−A$5.5M−3,317.7%
Interest & other expense
−A$1.1M−694.2%
Net income
−A$6.6M−4,011.9%

Each bar shows an amount and its share of revenue. GELS kept −4,011.9% of revenue as net income.

GELS profit margins

GrossOperatingNet

GELS growth rates

to FY2025
1 year3 years5 years10 years
Revenue—+3.9%——
Gross profit—+46.5%——
Operating income————
Net income————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

GELS income statement in Australian dollars

Gelteq Limited annual income statement
FY2025FY2024FY2023FY2022FY2021FY2020
RevenueA$165,645A$0A$79,843A$147,536A$0A$0
Cost of revenueA$0A$0A$48,925A$94,874A$0—
Gross profitA$165,645A$0A$30,918A$52,662A$0—
Research & developmentA$628,606A$276,057A$665,035A$529,017A$277,055A$342,357
Sales, general & adminA$2.2MA$1.3MA$1.7MA$1.5MA$450,954A$168,688
Total operating expensesA$5.7MA$2.9MA$3.1MA$3.2MA$647,624A$529,620
Operating income−A$5.5M−A$2.9M−A$3.1M−A$3.2M−A$647,624—
Interest expenseA$1.9MA$585,120A$403,521A$174,503A$1,297—
Income before taxes−A$6.6M−A$3.5M−A$3.5M−A$3.4M−A$648,921−A$529,620
Income taxes—————−A$154,033
Net income−A$6.6M−A$3.5M−A$3.5M−A$3.4M−A$648,921−A$375,587
EBITDA−A$3.5M−A$1.8M−A$1.9M−A$2.0M−A$589,679−A$527,233
Gross margin100.0%—38.7%35.7%——
Operating margin−3,317.7%—−3,885.3%−2,164.4%——
Net margin−4,011.9%—−4,391.4%−2,283.4%——

Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported in GELS's financial statements (latest annual report filed June 30, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.

GELS financial results

In fiscal year 2025 (ended June 30, 2025), Gelteq reported revenue of A$0.2 million. It had a net loss of A$6.6 million, a net profit margin of −4,011.9%. Figures are in Australian dollars, the currency of its financial statements.

See the GELS stock overview for the latest quote and news, or the GELS chart for price history and technical indicators.

GELS income statement FAQ

What is Gelteq's annual revenue?

Gelteq reported total revenue of A$0.2 million for fiscal year 2025, which ended on June 30, 2025.

Is Gelteq profitable?

No. Gelteq reported a net loss of A$6.6 million in fiscal 2025, a net profit margin of −4,011.9%; its operating margin was −3,317.7%.

What is Gelteq's gross margin?

Gelteq's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Gelteq kept $100 after the direct cost of its products and services.

How much does Gelteq spend on research and development?

Gelteq spent A$0.6 million on research and development in fiscal 2025, 379.5% of revenue.

When does Gelteq's fiscal year end?

Gelteq's fiscal year ends in June. The latest annual report covers the year ended June 30, 2025 and was filed on June 30, 2025.

Drug Manufacturers - Specialty & Generic income statements